Therapeutical potential of a peptide mimicking the SOCS1 kinase inhibitory region in skin immune responses
- PMID: 23592500
- DOI: 10.1002/eji.201343370
Therapeutical potential of a peptide mimicking the SOCS1 kinase inhibitory region in skin immune responses
Abstract
IFN-γ-activated keratinocytes are key contributors to the pathogenetic mechanisms leading to type-1 immune-mediated skin disorders. In these epidermal cells, SOCS1 negatively regulates the molecular cascades triggered by IFN-γ by disabling JAK2 phosphorylation through its kinase inhibitory region (KIR). Aimed at potentiating the SOCS1 inhibitory function on JAK2/STAT1 axis in keratinocytes, we recently developed a set of peptides mimicking the SOCS1 KIR domain, which are capable of efficiently binding JAK2 in vitro. Here, the effects of one such SOCS1 KIR mimetic named PS-5 on IFN-γ-activated human keratinocytes were evaluated. We found that IFN-γ-activated keratinocytes treated with PS-5 exhibited impaired JAK2, IFN-γRα, and STAT1 phosphorylation. We also observed reduced levels of the IRF-1 transcription factor, and a strong reduction in ICAM-1, HLA-DR, CXCL10, and CCL2 inflammatory gene expression. ICAM-1 reduced expression resulted in an impaired adhesiveness of T lymphocytes to autologous keratinocytes. Consistently, the migration of T cells toward supernatants from PS-5-treated keratinocytes was drastically reduced. Finally, PS-5 treatment hampered STAT1 activation and the expression of STAT1-dependent inflammatory genes in IFN-γ-treated explants of human skin. These data collectively indicate that PS-5 has an important therapeutic potential in the treatment of type-1 immune-mediated skin diseases.
Keywords: Epidermal keratinocytes; IFN-γ-signaling; SOCS1; Skin inflammation.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Comment in
-
Therapeutic hope for psoriasis offered by SOCS (suppressor of cytokine signaling) mimetic peptide.Eur J Immunol. 2013 Jul;43(7):1702-5. doi: 10.1002/eji.201343748. Eur J Immunol. 2013. PMID: 23828297
Similar articles
-
SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation.Front Immunol. 2024 Jun 21;15:1393799. doi: 10.3389/fimmu.2024.1393799. eCollection 2024. Front Immunol. 2024. PMID: 38975347 Free PMC article. Review.
-
Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1.J Immunol. 2002 Jul 1;169(1):434-42. doi: 10.4049/jimmunol.169.1.434. J Immunol. 2002. PMID: 12077274
-
The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Krüppel-like factor-4, and it is dysregulated in psoriatic keratinocytes.J Immunol. 2010 Aug 15;185(4):2467-81. doi: 10.4049/jimmunol.1001426. Epub 2010 Jul 19. J Immunol. 2010. PMID: 20644166
-
SOCS1-negative feedback of STAT1 activation is a key pathway in the dsRNA-induced innate immune response of human keratinocytes.J Invest Dermatol. 2006 Jul;126(7):1574-81. doi: 10.1038/sj.jid.5700294. Epub 2006 Apr 20. J Invest Dermatol. 2006. PMID: 16628196
-
SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function.Front Immunol. 2015 Apr 21;6:183. doi: 10.3389/fimmu.2015.00183. eCollection 2015. Front Immunol. 2015. PMID: 25954276 Free PMC article. Review.
Cited by
-
SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation.Front Immunol. 2024 Jun 21;15:1393799. doi: 10.3389/fimmu.2024.1393799. eCollection 2024. Front Immunol. 2024. PMID: 38975347 Free PMC article. Review.
-
Inflammatory Skin Diseases: Focus on the Role of Suppressors of Cytokine Signaling (SOCS) Proteins.Cells. 2024 Mar 13;13(6):505. doi: 10.3390/cells13060505. Cells. 2024. PMID: 38534350 Free PMC article. Review.
-
SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity.Front Immunol. 2024 Feb 13;15:1362224. doi: 10.3389/fimmu.2024.1362224. eCollection 2024. Front Immunol. 2024. PMID: 38415248 Free PMC article.
-
SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.Front Immunol. 2023 Oct 26;14:1271102. doi: 10.3389/fimmu.2023.1271102. eCollection 2023. Front Immunol. 2023. PMID: 38022642 Free PMC article. Review.
-
SOCS1 Peptidomimetic Alleviates Glomerular Inflammation in MsPGN by Inhibiting Macrophage M1 Polarization.Inflammation. 2023 Dec;46(6):2402-2414. doi: 10.1007/s10753-023-01886-3. Epub 2023 Aug 15. Inflammation. 2023. PMID: 37581761
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous